National Institute Of Cardiology, Warsaw, Poland
Clinical trials sponsored by National Institute Of Cardiology, Warsaw, Poland, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a diabetes drug boost heart function in non-diabetic patients? Results expected Sep 2026 (estimated)
- Earlier blood thinner may cut clot risk in heart procedures Results expected Jan 2027 (estimated)
- New registry aims to unlock secrets of rare heart disease from gut tumors Results expected Jun 2027 (estimated)
-
Earlier blood thinner may cut clot risk in heart procedures
Disease control By invitation onlyResearchers compare two timings for giving the blood thinner heparin during minimally invasive heart procedures that require a puncture through the wall between the heart's upper chambers. Adults scheduled for mitral valve repair or left atrial appendage closure join the trial. O…
Phase 4 • Sponsor: National Institute of Cardiology, Warsaw, Poland • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a diabetes drug boost heart function in non-diabetic patients?
Symptom relief OngoingThis study tests whether empagliflozin, a drug typically used for diabetes, can help people with hypertrophic cardiomyopathy (a thickened heart muscle) who do not have diabetes. About 250 adults will receive either the drug or a placebo daily for 12 months. The main goals are to …
Phase 3 • Sponsor: National Institute of Cardiology, Warsaw, Poland • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC